| [1] |
Bell S, Fletcher EH, Brady I, et al. End-stage renal disease and survival in people with diabetes: a national database linkage study [J]. QJM, 2015, 108(2): 127-134.
|
| [2] |
Heerspink HJL, Parving HH, Andress DL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial [J]. Lancet, 2019, 393(10184): 1937-1947.
|
| [3] |
National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update [J]. Am J Kidney Dis, 2012, 60(5): 850-886.
|
| [4] |
American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020 [J]. Diabetes Care, 2020, 43(Suppl 1): S14-S31.
|
| [5] |
Doshi SM, Friedman AN. Diagnosis and management of type 2 diabetic kidney disease [J]. Clin J Am Soc Nephrol, 2017, 12(8): 1366-1373.
|
| [6] |
Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy [J]. N Engl J Med, 2013, 369(20): 1892-903.
|
| [7] |
Orbay H, Tobita M, Mizuno H. Mesenchymal stem cells isolated from adipose and other tissues: basic biological properties and clinical applications [J]. Stem Cells Int, 2012, 2012: 461718.
|
| [8] |
Venkat P, Shen Y, Chopp M, et al. Cell-based and pharmacological neurorestorative therapies for ischemic stroke [J]. Neuropharmacology, 2018, 134(Pt B): 310-322.
|
| [9] |
Mennan C, Brown S, McCarthy H, et al. Mesenchymal stromal cells derived from whole human umbilical cord exhibit similar properties to those derived from Wharton′s jelly and bone marrow [J]. FEBS Open Bio, 2016, 6(11): 1054-1066.
|
| [10] |
Peired AJ, Sisti A, Romagnani P. Mesenchymal stem cell-based therapy for kidney disease: a review of clinical evidence [J]. Stem Cells Int, 2016, 2016: 4798639.
|
| [11] |
Zhang Q, Fu L, Liang Y, et al. Exosomes originating from MSCs stimulated with TGF-β and IFN-γ promote Treg differentiation [J]. J Cell Physiol, 2018, 233(9): 6832-6840.
|
| [12] |
Liu H, Liang Z, Wang F, et al. Exosomes from mesenchymal stromal cells reduce murine colonic inflammation via a macrophage-dependent mechanism [J]. JCI Insight, 2019, 4(24): e131273.
|
| [13] |
Baharlooi H, Azimi M, Salehi Z, et al. Mesenchymal stem cell-derived exosomes: a promising therapeutic ace card to address autoimmune diseases [J]. Int J Stem Cells, 2020, 13(1): 13-23.
|
| [14] |
Phinney DG, Pittenger MF. Concise review: MSC-derived exosomes for cell-free therapy [J]. Stem Cells, 2017, 35(4): 851-858.
|
| [15] |
Wolfers J, Lozier A, Raposo G, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming [J]. Nat Med, 2001, 7(3): 297-303.
|
| [16] |
André F, Schartz NE, Chaput N, et al. Tumor-derived exosomes: a new source of tumor rejection antigens [J]. Vaccine, 2002, 20(Suppl 4): A28-A31.
|
| [17] |
Romagnoli GG, Zelante BB, Toniolo PA, et al. Dendritic cell-derived exosomes may be a tool for cancer immunotherapy by converting tumor cells into immunogenic targets [J]. Front Immunol, 2015, 5: 692.
|
| [18] |
Tang XJ, Sun XY, Huang KM, et al. Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy [J]. Oncotarget, 2015, 6(42): 44179-44190.
|
| [19] |
Lu J, Wu J, Tian J, et al. Role of T cell-derived exosomes in immunoregulation [J]. Immunol Res, 2018, 66(3): 313-322.
|
| [20] |
Liu Y, Lou G, Li A, et al. AMSC-derived exosomes alleviate lipopolysaccharide/d-galactosamine-induced acute liver failure by miR-17-mediated reduction of TXNIP/NLRP3 inflammasome activation in macrophages [J]. EBioMedicine, 2018, 36: 140-150.
|
| [21] |
Wu Y, Li J, Yuan R, et al. Bone marrow mesenchymal stem cell-derived exosomes alleviate hyperoxia-induced lung injury via the manipulation of microRNA-425 [J]. Arch Biochem Biophys, 2021, 697: 108712.
|
| [22] |
Li Z, Liu F, He X, et al. Exosomes derived from mesenchymal stem cells attenuate inflammation and demyelination of the central nervous system in EAE rats by regulating the polarization of microglia [J]. Int Immunopharmacol, 2019, 67: 268-280.
|
| [23] |
Hassanzadeh A, Rahman HS, Markov A, et al. Mesenchymal stem/stromal cell-derived exosomes in regenerative medicine and cancer; overview of development, challenges, and opportunities [J]. Stem Cell Res Ther, 2021, 12(1): 297.
|
| [24] |
Liu W, Rong Y, Wang J, et al. Exosome-shuttled miR-216a-5p from hypoxic preconditioned mesenchymal stem cells repair traumatic spinal cord injury by shifting microglial M1/M2 polarization [J]. J Neuroinflammation, 2020, 17(1): 47.
|
| [25] |
Soundara Rajan T, Giacoppo S, Diomede F, et al. Human periodontal ligament stem cells secretome from multiple sclerosis patients suppresses NALP3 inflammasome activation in experimental autoimmune encephalomyelitis [J]. Int J Immunopathol Pharmacol, 2017, 30(3): 238-252.
|
| [26] |
Moghadasi S, Elveny M, Rahman HS, et al. A paradigm shift in cell-free approach: the emerging role of MSCs-derived exosomes in regenerative medicine [J]. J Transl Med, 2021, 19(1): 302.
|
| [27] |
Hooijmans CR, Rovers MM, de Vries RB, et al. SYRCLE′s risk of bias tool for animal studies [J]. BMC Med Res Methodol, 2014, 14: 43.
|
| [28] |
Wang S, Bao L, Fu W, et al. Protective effect of exosomes derived from bone marrow mesenchymal stem cells on rats with diabetic nephropathy and its possible mechanism [J]. Am J Transl Res, 2021, 13(6): 6423-6430.
|
| [29] |
Nagaishi K, Mizue Y, Chikenji T, et al. Mesenchymal stem cell therapy ameliorates diabetic nephropathy via the paracrine effect of renal trophic factors including exosomes [J]. Sci Rep, 2016, 6: 34842.
|
| [30] |
Li H, Rong P, Ma X, et al. Mouse umbilical cord mesenchymal stem cell paracrine alleviates renal fibrosis in diabetic nephropathy by reducing myofibroblast transdifferentiation and cell proliferation and upregulating MMPs in mesangial cells [J]. J Diabetes Res, 2020, 2020: 3847171.
|
| [31] |
Duan YR, Chen BP, Chen F, et al. Exosomal microRNA-16-5p from human urine-derived stem cells ameliorates diabetic nephropathy through protection of podocyte [J]. J Cell Mol Med, 2021, 25(23): 10798-10813.
|
| [32] |
Fineberg D, Jandeleit-Dahm KA, Cooper ME. Diabetic nephropathy: diagnosis and treatment [J]. Nat Rev Endocrinol, 2013, 9(12): 713-723.
|
| [33] |
Sierra-Mondragon E, Molina-Jijon E, Namorado-Tonix C, et al. All-trans retinoic acid ameliorates inflammatory response mediated by TLR4/NF-κB during initiation of diabetic nephropathy [J]. J Nutr Biochem, 2018, 60: 47-60.
|
| [34] |
Arora MK, Singh UK. Oxidative stress: meeting multiple targets in pathogenesis of diabetic nephropathy [J]. Curr Drug Targets, 2014, 15(5): 531-538.
|
| [35] |
Lagies S, Pichler R, Bork T, et al. Impact of diabetic stress conditions on renal cell metabolome [J]. Cells, 2019, 8(10): 1141-1141.
|
| [36] |
Chawla D, Bansal S, Banerjee BD, et al. Role of advanced glycation end product (AGE)-induced receptor (RAGE) expression in diabetic vascular complications [J]. Microvasc Res, 2014, 95: 1-6.
|
| [37] |
Jiang W, Li Z, Zhao W, et al. Breviscapine attenuated contrast medium-induced nephropathy via PKC/Akt/MAPK signalling in diabetic mice [J]. Am J Transl Res, 2016, 8(2): 329-341.
|
| [38] |
陈辛玲，王生兰. 细胞自噬过程、通路、调控及其与肺动脉高压的多重相关性[J].中国组织工程研究，2021, 25(2): 311-316.
|
| [39] |
郭园园. AGEs通过诱导巨噬细胞自噬影响糖尿病创面愈合的机制研究[D]. 上海：上海交通大学，2016.
|
| [40] |
Prasad A, Lane JR, Tsimikas S, et al. Plasma levels of advanced glycation end products are related to the clinical presentation and angiographic severity of symptomatic lower extremity peripheral arterial disease [J]. Int J Angiol, 2016, 25(1): 44-53.
|
| [41] |
Lenoir O, Jasiek M, Hénique C, et al. Endothelial cell and podocyte autophagy synergistically protect from diabetes-induced glomerulosclerosis [J]. Autophagy, 2015, 11(7): 1130-1145.
|
| [42] |
Cui X, Zhu L, Zhai R, et al. Mesenchymal stem cell-derived exosomes: a promising vector in treatment for diabetes and its microvascular complications [J]. Am J Transl Res, 2021, 13(5): 3942-3953.
|